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It has long been known that proton radiotherapy has an increased biological effectiveness 
compared to traditional x-ray radiotherapy.  This arises from the clustered nature of DNA 
damage produced by the energy deposition of protons along their tracks in medium.  This effect 
is currently quantified in clinical settings by assigning protons a relative biological effectiveness 
(RBE) value of 1.1 corresponding to 10% increased effectiveness compared to photon radiation.  
Numerous studies have shown, however, that the RBE value of protons is variable and can 
deviate substantially from 1.1, but experimental data on RBE and clinical evidence of its 
variability remains limited. 
The potential for using the variable RBE of proton radiation to improve clinical treatment 
plans has been theorized, but it is accepted that more experimental in vitro and in vivo data are 
needed before clinical adaptation of these techniques may occur.  Nevertheless, it will be 
important to identify strategies in which the variable nature of proton RBE may be used to 
inform treatment planning.  The goal of this work is thus to investigate if the assumption of a 
constant proton RBE has an adverse effect in current clinical applications and if the variable 
biological effectiveness of protons can be quantified from clinical data.   
First, results from high-resolution experiments quantifying proton RBE are compared to 
multiple models for calculating RBE.  A new model is then proposed which can more accurately 
reproduce the experimental results.  These models are implemented in a Monte Carlo-based 
dose calculation system and their output is compared for a cohort of pediatric patients treated for 
vii 
 
brain tumors with proton radiotherapy who subsequently presented with post-treatment image 
changes identified on magnetic resonance imaging.  One RBE model is identified as the best 
candidate for further study; however, results of volumetric analyses of RBE-weighted dose 
prove inconclusive in correlating with image changes.  A model is developed that can describe 
the probability of voxel-level image changes (signifying normal tissue damage) based on proton 
dose and linear energy transfer.  The model constitutes the first clinical evidence for the variable 
biological effectiveness of protons and holds promise for the improvement of proton therapy 
treatment planning. 
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Chapter 1: Introduction 
 
1.1. Proton Therapy 
Proton therapy is a radiation treatment modality that first came into use in the 1950s.  For 
many years its use remained limited due to a small number of available facilities; however, 
recent years have seen a dramatic increase in the number of proton therapy centers across the 
globe.  This increase in adoption is certainly due in part to the physical phenomenon, the Bragg 
peak, which provides protons a theoretical advantage over other standard photon radiation 
treatment modalities.  As protons travel through a material, such as human tissue, they gradually 
lose energy through Coulomb scattering and nuclear interactions and the rate of energy loss 
increases as they slow down.  Thus, nearing the end of their range, they rapidly deposit the 
remainder of their energy in a characteristic Bragg peak, after which the protons essentially 
stop, leaving little to no dose.  This is an appealing characteristic as proper planning would 
allow one to deliver appropriate proton radiation dose to a tumor while delivering lower dose to 
the structures proximal to the tumor and also nearly completely sparing the structures distal to 
the tumor. 
Proton’s ability to deposit dose at differing rates at different depths is due to the physical 
property known as linear energy transfer (LET).  This value specifically quantifies the rate at 
which protons transfer their energy to medium and is dependent on the stopping power of a 
proton which is in turn dependent on the proton energy.  As the energy of protons decreases as 
they traverse a medium, i.e. as they transfer more of their energy to the medium, the stopping 
power of the protons increases and thus the LET or rate at which the protons transfer their 
energy increases.  Furthermore, while proton dose deposition decreases beyond the Bragg peak, 
the LET continues to increase with the highest values being achieved beyond the peak.  An  
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Figure 1: Proton beamlet depth dose and LETd for initial beam energies of 79.7 MeV and 
219.3 MeV. 
Proton beamlet depth doses (solid lines) are presented for beamlets with initial energy of 79.7 
MeV (red) and 219.3 MeV (black).  Corresponding dose-averaged LET (LETd) is also presented 
for each beam energy. 
 
example of proton dose and dose-averaged LET (LETd) profiles in medium for two different 
initial proton energies is presented as an example in Figure 1.  The concept of LETd will be 
discussed in detail in Section 1.2. 
Over the years several different strategies for delivering proton radiation to treat cancer have 
been developed.  The more traditional method of delivery is known as passively scattered proton 
therapy (PSPT).  In this modality, an initial pristine proton beam that has been extracted from a 
synchrotron or cyclotron is first scattered to create a broad beam1.  After passing through 
necessary beam monitoring devices, the beam is then spread longitudinally with what is 
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generally referred to as a range modulator2.  This device, which may consist of a metal wheel of 
varying thickness, serves to create what is known as a spread out Bragg peak (SOBP)2.  The 
SOBP is designed such that it will uniformly deliver dose over the depth axis of the tumor2.  The 
edges of the proton beam are then shaped by a patient specific aperture, and the distal edge of 
the beam is shaped to the tumor with a patient specific compensator.  Multiple beams are 
normally used in order to reduce the dose received by the normal tissues encountered by the 
beams.  The name and specific design of the various components may differ at each particular 
treatment facility. 
More recent years have seen the rise of a treatment technique known as intensity modulated 
proton therapy (IMPT) which has been made possible by increases in available computational 
power and advancements in the technology itself.  In IMPT the range modulator and 
compensator components of the beamline are omitted.  Instead, numerous “pristine” Bragg 
peaks are used to deliver radiation dose to the tumor3,4.  Energy modulation, i.e. a sequence of 
beam energies, is used to vary the range of the individual beamlets while steering magnets are 
used to determine their lateral placement3,4.  Collectively, the dose from the beamlets, normally 
impinging from two or more beam directions, results in the delivery of the prescribed dose5. 
IMPT is the more powerful form of proton therapy due to its ability to provide improved 
normal tissue sparing.  This benefit, however, comes at the cost of greater vulnerability to 
uncertainties with the loss of homogeneity of individual beams and the potential for dose “hot 
spots”, focal areas of increased dose, within the target6,7.  It may also result in the shifting of 
higher LET components of individual beams into locations that they may not have appeared 
previously8,9.  This could potentially become an issue when one considers that the LET 
characteristics of protons result in an increased capability for cell kill compared to photon 
radiation10–12. 
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1.2. LET Calculation in Proton Therapy 
In order to properly quantify any increased capability for cell kill for proton beams, it is first 
necessary to be able to accurately calculate the LET of protons.  While an individual proton may 
have an LET value at a given location, it is often necessary and more practical to consider an 
average value over many protons traversing an area or volume.  A method for calculating LET 
as a weighted average over different quantities has been described by Wilkens and Oelfke13.  
According to their method, LET at a given depth or location may be calculated either as a track- 
or fluence-averaged quantity or as a dose-averaged quantity over protons of all residual ranges 
at that location.  In a publication by Guan and Peeler et al.12, the formalism by Wilkens and 
Oelfke13 was rewritten in terms of proton energy instead of residual range, though these are 
essentially equivalent as the residual range corresponds to a proton energy.  The track-averaged 
LET (LETt) may thus be calculated according to  
 
𝐿𝐸𝑇𝑡(𝑧) =  
∫ 𝑆𝑒𝑙(𝐸)𝜙(𝐸, 𝑧)𝑑𝐸
∞
0
∫ 𝜙(𝐸, 𝑧)𝑑𝐸
∞
0
 ( 1 ) 
where in the numerator, the product of the electronic stopping power (Sel)  and fluence (ϕ) for a 
given proton energy are integrated over all protons of all energies at the location z along the 
depth12.  The denominator is the sum of the fluences of all protons of all energies at that 
location, which is simply the total fluence.  Thus, the quantity is averaged over the fluence, 
lending to the “fluence-averaged” designator; however, this quantity is often referred to as the 
LETt in practice
12,13.  The dose-averaged LET (LETd) may be calculated in a similar manner 
according to 
 
𝐿𝐸𝑇𝑑(𝑧) =  
∫ 𝑆𝑒𝑙(𝐸)𝐷(𝐸, 𝑧)𝑑𝐸
∞
0
∫ 𝐷(𝐸, 𝑧)𝑑𝐸
∞
0
 ( 2 ) 
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where D(E,z) is the dose from a given energy of protons, E, at a location, z12.  The dose is a 
function of the electronic stopping power and fluence given by 
 
𝐷(𝐸, 𝑧) =
𝑆𝑒𝑙𝜙(𝐸, 𝑧)
𝜌(𝑧)
 ( 3 ) 
where ρ(z) is the density of the medium at location z12.  At any given location, the values for 
LETt and LETd will vary depending on the spectrum of proton energies present; however, as 
indicated by Guan and Peeler et al. the differences between LETt and LETd most notably occur 
near the end of the proton range in the region at or beyond the Bragg peak12.  It is in this region 
that the LETt provides an underestimation compared to the LETd.  In low LET regions, the 
values of the two quantities are observed to agree well12. 
For the purposes of this study, LETt and LETd are both utilized in differing situations 
primarily according to the data available to perform the calculations.  In particular, LETd 
requires decoupled energy spectrum and fluence data in order to properly perform the dose-
averaging operation.  It is thus necessary to consider where these two quantities are equivalent 
and not equivalent when evaluating the results.  In either case, the average LET has generally 
been considered an acceptable surrogate for the biological effectiveness of protons and most of 
the published work on this topic has relied on average LET values.  Increasingly, however, 
averaged LET is being realized to be a less accurate index of biological effect. 
 
1.3. Relative Biological Effectiveness 
It has long been known that light and heavy ions have an increased biological effect in tissue 
compared to traditional photon treatment modalities.  This increased effectiveness is known as 
the relative biological effectiveness (RBE), which refers to the relative increase in the capability 
for cell kill of an ion or other modality compared to a traditional photon based modality, such as 
x-rays or Co-60 gamma rays.  It is specifically defined as the ratio of a reference photon dose to 
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the dose of a radiation type/quality of interest that results in the same biological effect and is 
represented by the following equation 
 
𝑅𝐵𝐸 =  
𝐷𝑥
𝐷𝑡
 ( 4 ) 
in which Dx is the reference photon dose and Dt is the dose of a test radiation of interest 
(henceforth Dt will be referred to as Dp because this study focuses specifically on protons).  The 
reason for this increased RBE for ions lies in the nature of their energy deposition, specifically 
that it is concentrated along the ion track leading to more localized DNA damage and a higher 
number of complex double strand breaks (DSBs)14.  For protons, the value of the RBE has long 
been assumed to be 1.1 meaning that protons are 10% more effective than photons with regard 
to killing cells.  The selection of this value was largely determined based on in vitro 
experimental data and limited in vivo data; however, based on this same data, the value is 
known to vary from 1.0 to as high as 3.0 or even higher in some cases11,15–20.  Despite this fact, 
the International Commission on Radiation Units (ICRU) recommends that a constant value of 
1.1 be used as the RBE of protons for the purposes of clinical treatment planning and delivery 
due to a lack of convincing clinical evidence to support the use of other values21. 
The more recent comprehensive assessments of proton RBE have been conducted by 
Paganetti et al.18,20  His 2002 study aimed to collect and summarize much of the accumulated 
knowledge of proton RBE and make some assessment as to how the information should be 
utilized moving forward.  This work reaffirmed the fact that proton RBE may vary around the 
accepted value of 1.1 and also noted that underestimations of the RBE on the order of 10% 
could present clinically significant consequences18.  In 2014, Paganetti again performed a 
comprehensive review of the available experimental data for proton RBE20.  This study 
collected and evaluated 369 data points from proton cell survival experiments obtained from 76 
publications20.  Beyond simply summarizing results, Paganetti’s study in some cases provided 
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newly calculated LET values when they were unavailable in the original publication.  The end 
result was a thorough view of the published results of proton RBE for a range of clinically 
relevant LET values.  The results were summarized by stating that the RBE of protons varies 
from 1.1 in the entrance/plateau region ranging up to 1.35 at the distal edge of the Bragg peak.  
The average value reported for the distal falloff region was 1.720.  This study underlines the 
continual importance of the evaluation of new literature and also the value of more experimental 
data in contributing to the overall knowledge of proton RBE. 
A more recent set of published results is of additional interest.  A study by Chaudhary et al.11 
evaluated proton RBE through cell survival experiments in a consistent and thorough manner 
for both a pristine Bragg peak and an SOBP11.  Experiments were performed for both the 
AG01522 normal human skin fibroblast cell line and U87 radioresistant human glioma cell 
line11.  RBE values were measured for a range of positions along the beam depth dose profiles 
corresponding to LETd values up to ~25 keV µm
-1.  For a cell surviving fraction of 10%, RBE 
values between 2.0 and 2.5 were reported for LETd values of 20-25 keV µm
-1 11.  Such LETd 
values are high and would typically be encountered in the distal falloff region, but this remains 
of relevance because this region of the proton depth dose distribution often deposits energy in 
normal tissue structures beyond the tumor target.  The observed high RBE values are thus of 
concern with regard to traditional treatment planning techniques and the potential for high RBE 
protons to deposit dose outside of the target. 
It is still believed that the current experimental knowledge of proton RBE is not sufficient to 
make sweeping changes to the standard of practice of constancy of RBE and clear clinical 
evidence would be required to provide sufficient impetus for change18.  The aim of this work is 
thus not to directly suggest altering current clinical practice, but rather to determine if clinical 
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evidence supporting the use of variable RBE can be extracted from current outcomes observed 
in proton therapy. 
 
1.4. Variable RBE Models 
In more recent years, various groups have investigated and implemented means of 
accounting for the variable nature of proton RBE in dose calculation22–28.  This has led to the 
development of several different methods of calculating or accounting for proton RBE, each of 
which assumes a different name.  Such methods, however, may collectively be referred to as 
variable RBE models: models which accept various forms of input data to calculate proton RBE 
at any particular point of dose calculation.  The primary basis for these models is a 
radiobiological model known as the linear-quadratic (LQ) model.  This model describes the 
nature of the response of living cells to radiation.  For a given type of radiation, a plot of cell 
surviving fraction (SF) with respect to delivered radiation dose (D) may be represented by 
 𝑆𝐹 = 𝑒−𝛼𝐷−𝛽𝐷
2
 ( 5 ) 
in which α and β are coefficients specific to the type of cells being irradiated.  The coefficients 
are generally determined by fitting the results of clonogenic cell survival experiments with the 
model.  According to the definition of RBE, the LQ equations for survival fraction for the 
reference photon dose and proton dose may be used to solve for the ratio of these doses.  
Simplifying the result provides the following equation 
 
𝑅𝐵𝐸 =
𝐷𝑥
𝐷𝑝
=
√𝛼𝑥2 + 4𝛽𝑥𝐷𝑝 (𝛼 + 𝛽𝐷𝑝) − 𝛼𝑥
2𝛽𝑥𝐷𝑝
 
( 6 ) 
in which αx and βx are the biological coefficients for photons and α and β are the coefficients for 
protons22.  This equation thus provides a means to calculate RBE as a function of photon and 
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proton biological coefficients and proton dose.  It is important to note, though, that the 
published data for the biological coefficients for protons is limited. 
Carabe-Fernandez et al.27,28 later proposed a new parameterization of the basic RBE model 
incorporating the concepts of an RBEmax and RBEmin.  These are asymptotic relationships based 
on either the dose approaching zero or infinity, respectively.  RBEmax is represented by  
 𝑅𝐵𝐸𝑚𝑎𝑥 =
𝛼
𝛼𝑥
 ( 7 ) 
where dose is assumed to approach zero.  RBEmin is represented by  
 
𝑅𝐵𝐸𝑚𝑖𝑛 = √
𝛽
𝛽𝑥
 ( 8 ) 
where dose is assumed to approach infinity.  In order to incorporate this concept into the RBE 
model in Equation ( 6 ), the model must first be rewritten in terms of the ratios of the α and β 
values.  The resulting formula is represented by Equation ( 9 ) 
 
𝑅𝐵𝐸 =  
𝐷𝑥
𝐷𝑝
= −
1
2𝐷𝑝
(
𝛼
𝛽
)
𝑥
+
1
𝐷𝑝
√
1
4
(
𝛼
𝛽
)
𝑥
2
+
𝛼
𝛼𝑥
(
𝛼
𝛽
)
𝑥
𝐷𝑝 +
𝛽
𝛽𝑥
𝐷𝑝2 ( 9 ) 
which is now also written in terms of the ratio of αx and βx27,29.  All of the models used in this 
study are thus rewritten to follow this standard form as in many cases it removes the dependence 
on proton α and β values. 
Six published models for proton RBE will be used for the analysis in this study.  The RBEmax 
and RBEmin parameterizations for all of the models are presented in Table 1 and Table 2, 
respectively.  The first model to be discussed may be referred to as the phenomenological model 
or the Wilkens and Oelfke model after the scientists that proposed it22.  The objective in the 
development of this model was to create something based on the linear-quadratic model and that 
could be fitted and tested according to existing experimental results22.  Given that biological 
factor data for reference x- ray radiation is more abundant than that for protons, it was deemed 
10 
 
Table 1: Equations for RBEmax for selected RBE models. 
The RBEmax formalisms for six selected RBE models are collected here.  In some cases the 
equations have been rewritten from the originally published form to match the RBEmax 
definition. 
Model RBEmax (
𝛼
𝛼𝑥
) Equation # 
Wilkens and Oelfke22,30 1 +
𝜆
𝛼𝑥
(𝐿𝐸𝑇𝑑 − 0.5 𝑘𝑒𝑉 𝜇𝑚
−1) ( 10 ) 
Wedenberg et al.25 1 +
0.434
(𝛼/𝛽)𝑥
𝐿𝐸𝑇𝑑 ( 11 ) 
Carabe-Fernandez et al.27,28,31  0.843 + 0.154
2.686
(𝛼/𝛽)𝑥
𝐿𝐸𝑇𝑑 ( 12 ) 
McNamara et al.32 0.999064 +
0.35605
(𝛼/𝛽)𝑥
𝐿𝐸𝑇𝑑 ( 13 ) 
Chen and Ahmad26 
1
𝛼𝑥
(0.1 +
1 − 𝑒−0.0013𝐿𝐸𝑇𝑑
2
0.045𝐿𝐸𝑇𝑑
) ( 14 ) 
RMF23,24,29,33 𝑅𝐵𝐸𝐷𝑆𝐵 (1 +
𝑧?̅?𝑅𝐵𝐸𝐷𝑆𝐵
(𝛼/𝛽)𝑥
) ( 15 ) 
 
 
prudent to parameterize this equation to depend only on coefficients for x-rays22.  It was 
identified that a linear relationship based on the LETd of protons could be used to relate the 
proton α value to that of x-rays based on experimental data for V79 Chinese hamster cells from 
studies by Goodhead et al.34, Blomquist et al.35, Belli et al.10,15, Folkard et al.36, Wouters et al.16, 
and Schettino et al.37  A linear scaling factor λ is used to describe the change in the proton α 
with LETd.  Very little conclusive data regarding the β coefficient for protons is available, so it 
was deemed best to  
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Table 2: Equations for RBEmin for selected RBE models. 
The RBEmin formalisms for six selected RBE models are collected here.  Values of 1 indicate 
that the β for protons was assumed to be equal to that of photons. 
Model RBEmin (√
𝛽
𝛽𝑥
) Equation # 
Wilkens and Oelfke22 1 ( 16 ) 
Wedenberg et al.25 1 ( 17 ) 
Carabe-Fernandez et al.27,28,31  1.09 + 0.006
2.686
(𝛼/𝛽)𝑥
𝐿𝐸𝑇𝑑 ( 18 ) 
McNamara et al.32 1.1012 − 0.0038703√(𝛼/𝛽)𝑥𝐿𝐸𝑇𝑑 ( 19 ) 
Chen and Ahmad26 1 ( 20 ) 
RMF23,24,29,33 𝑅𝐵𝐸𝐷𝑆𝐵 ( 21 ) 
 
 
simply set it equal to the β value for x-rays22.  In practice this model has been shown to 
reasonably replicate experimental data and has also been applied to calculate RWD distributions 
for individual treatment plans22,30,38.  The representation of the model in Equation ( 10 ) is 
adapted from that presented by Frese et al.30  Using the equations 
 𝛼 = 𝛼0 + 𝜆 ∗ 𝐿𝐸𝑇𝑑  ( 22 ) 
 
𝛼0 = 𝛼𝑥 − 0.5
𝑘𝑒𝑉
𝜇𝑚
∗ 𝜆 ( 23 ) 
where α0 is the initial α value or intercept, Equation ( 23 ) is substituted into Equation ( 22 ).  
The resulting equation is then divided by αx in order to produce an equation representative of 
RBEmax which is Equation ( 10 )30. 
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Another similar linear model of RBEmax with LET was published by Wedenberg et al.
25  In 
their model, 𝛼/𝛼𝑥 was fit as a linear function of LET, but the scaling parameter was written as 
an inverse relationship with (𝛼/𝛽)𝑥, such that for high values of (𝛼/𝛽)𝑥 the calculated RBE 
would be less dependent on LET25.  Analysis of previously published experimental data again 
led to the use of an RBEmin value of 1
25.  The RBEmax and RBEmin formalisms for this model are 
presented in Equations ( 11 ) and ( 17 ). 
The model by Carabe-Fernandez et al.31 was also determined through linear regression 
analysis of the results of previously published experiments.  The fitting was performed over data 
from many of the same experiments employed by Wilkens and Oelfke22 with additional data 
from Coutrakon et al.39  The exact form used for this work was published by Carabe-Fernandez 
et al. in 201231.  The models for RBEmax and RBEmin both scale linearly with LETd with the 
scaling term being inversely proportional to (𝛼/𝛽)𝑥.  RBEmax and RBEmin are represented by 
Equations ( 12 ) and ( 18 ), respectively. 
The last of the included models with a similar linear form for RBEmax and RBEmin is that by 
McNamara et al.32  Fitting of this model was performed over 287 experimental data points 
collected over numerous experiments in a review by Paganetti20.  The resulting model for 
RBEmax was a linear function of LET with the scaling term inversely proportional to (𝛼/𝛽)𝑥
32.  
The equation for RBEmin was also linear with LET; however, in this case the scaling term was 
directly proportional to √(𝛼/𝛽)𝑥 
32.  The formalisms for RBEmax and RBEmin are represented by 
Equations ( 13 ) and ( 19 ). 
A nonlinear model describing the change in α with LET for protons was described by Chen 
and Ahmad26.  This model was fit based on data from Wouters et al.16, Belli et al.10,15, and 
Folkard et al.36 and captured the observed decrease in α for high values of LET.  The value of β 
for protons was assumed to be a constant for the sake of simplicity26.  The model did not 
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incorporate scaling based on (𝛼/𝛽)𝑥.  The resulting equations with the fitted parameters are 
presented by Equations ( 14 ) and ( 20 ). 
Another model that is based more directly on the biological mechanisms involved in 
radiation damage is known as the repair-misrepair-fixation (RMF) model23,24,33.  The name is 
descriptive of the biological processes that are accounted for within the model.  The model as it 
is employed for this work is based on the concept of RBE of DSB induction (RBEDSB) 
employed by Polster et al.29 for implementation of the model into a Monte Carlo calculation 
framework.  RBEDSB is an extension of the definition of RBE to the relative number of DSBs 
induced by proton radiation compared to photon radiation for different proton radiation quality.  
The total number of DSBs generated in a cell by a given radiation quality is represented by the 
symbol Σ.  The RBEDSB can thus be represented by the equation 
 
𝑅𝐵𝐸𝐷𝑆𝐵 =
𝛴𝑝
𝛴𝑥
 ( 24 ) 
where Σp is the number of DSBs per Gray per giga base pair (DSB Gy-1 Gbp-1) for protons and 
Σx is the DSB Gy-1 Gbp-1 induced by photons for a given dose.  Values for Σ may be obtained 
using the Monte Carlo Damage Simulation (MCDS) software developed by Semenenko et 
al.24,40–43  This software serves to rapidly model the biological processes of DNA damage, repair, 
misrepair, and fixation in order to determine a total number of DSBs produced by a given 
radiation quality.  Equations ( 15 ) and ( 21 ) present the models for RBEmax and RBEmin as they 
are implemented in this work.  The term 𝑧?̅? in Equation ( 15 ) is the frequency-mean specific 
energy which is a microdosimetric term analogous to energy deposition or dose23.    The model 
has been shown to agree reasonably well with lower ion LET values, such as those that would 
be encountered in proton therapy23,24,43. 
Another model worth noting briefly is known as the local effect model (LEM).  This model 
was developed by Scholz and Kraft et al., building from an earlier model from Butts and Katz et 
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al., to address the issue of accurately accounting for RBE-weighted dose (RWD) for carbon ion 
therapy44–47.  The LEM model is based primarily on the radial dose deposition from ion tracks 
and uses this and information of track structure to determine the amount and location of DNA 
damage that occurs from a summation of individual tracks46,47.  This model is not as readily 
applicable for this study and thus will not be explored further. 
 
1.5. The General Radiation Dose-Response Model 
In the realm of photon therapy, the appropriate safe and effective doses used for patient 
treatment have largely been determined based on retrospective analyses of observed treatment 
outcomes.  The large collection of outcomes data obtained from many years of photon 
radiotherapy have been employed for the purpose of building models to describe the relationship 
of the delivered dose with both tumor and normal tissue response.  Such models are referred to 
as dose-response models, and a large collection of such models have been developed over the 
years.   
Some of the earliest and subsequently most cited work in this field was published by Lyman 
in the 1980s48.  Based on treatment outcome data, Lyman developed a model to describe normal 
tissue response based on volumes of delivered dose in organs of interest.  The probability of 
response predicted by the model is known as normal tissue complication probability (NTCP).  
The model developed by Lyman is based on the sigmoid-shaped curve produced by the probit 
function represented by Equation ( 25 ). 
 
𝑃 = 𝐹(𝑐|𝜇, 𝜎) =  
1
𝜎√2𝜋
∫ 𝑒
−
(𝑐−𝜇)2
2𝜎2
𝑐
−∞
𝑑𝑐 ( 25 ) 
Assuming mean µ = 0 and standard deviation σ =1 results in the following equation 
15 
 
 
𝑃 = 𝐹(𝑐) =  
1
√2𝜋
∫ 𝑒−
𝑐2
2
𝑐
−∞
𝑑𝑐 ( 26 ) 
which is the form of the equation employed by Lyman48.  Lyman parameterized the exponent of 
this model in terms of the tolerance dose (TD) at which a percentage of patients receiving that 
dose to a given volume of tissue would be expected to experience a certain response or 
complication.  The TD at which 50% of patients would be expected to experience a 
complication would be abbreviated as TD50, for example. Lyman’s parametrization of the 
exponent of the probit function is represented by 
 
𝑐 =
𝐷 − 𝑇𝐷(𝑉)
𝑚 ∗ 𝑇𝐷(𝑉)
 ( 27 ) 
where D is the delivered dose and m is a parameter that characterizes the slope of the probit 
curve48.  TD(V) describes the TD for a specific uniformly irradiated partial volume (V) of the 
anatomic structure.  TD(V) may be determined according to 
 
𝑇𝐷(𝑉) =
𝑇𝐷(1)
𝑉𝑛
 ( 28 ) 
where TD(1) is the TD for uniform irradiation of a whole organ volume, V is the irradiated 
volume of interest and n is a fitted parameter based on outcomes data for different organs48.  
This model was later expanded upon by Kutcher and Burman who developed the strategy to 
compute the equivalent uniformly irradiated partial volume from an arbitrary non-uniform 
irradiation49.  They also applied the model for fitting of collected outcomes data presented by 
Emami et al.50 and recorded the model parameters for 28 organs of interest constituting 29 
different endpoints51.  The more modern form of the model is referred to as the Lyman-Kutcher-
Burman or LKB model. 
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1.6. Patient Cohort of Interest 
One of the inherent physical advantages of proton therapy is its lack of exit dose and low 
entrance dose compared to the dose delivered at the target location.  In general the doses 
delivered to normal tissues in proton therapy are low compared to photon therapy due to the 
proton physical properties.  Such properties may be of special benefit for brain tumors in 
pediatric patients requiring radiotherapy, where low dose radiation exposure, seen even with 
advanced photon techniques, may be associated with significant radiation induced adverse 
effects, such as cognitive decline52,53.  It is thus of great interest to physicians when unexpected 
levels of adverse treatment effects are observed in this subset of patients, as the prevailing 
thought is that proton therapy should be the more favorable treatment modality54–57. 
A more recently published study by Gunther et al. observed that for a cohort of pediatric 
patients treated for brain tumors, specifically ependymoma, the patients treated with protons 
presented with post-treatment image changes on follow-up MRI at a higher rate than those 
patients treated with photons58.  These patients were treated on a prospective protocol 
comparing normal tissue toxicity between intensity-modulated photon therapy (IMRT) to PSPT.  
Radiotherapy type, months after surgery before radiotherapy, age at radiotherapy, and an 
interaction variable for radiotherapy type and age were examined on multivariate logistic 
regression analysis to determine association with the development of image changes58.  The 
radiotherapy type (proton therapy) was found to be the only significant factor (p = 0.024) 
associated with the development of image changes58. 
One of the most identifiable physical differences between proton and photon therapy is the 
nature of the LET of the modalities.  Proton LET is not constant along the proton beam path and 
is known to contribute to a variable biological effectiveness compared to photons.  It is thus of 
interest to study this particular cohort of patients due to their high rate of observed post-
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treatment normal tissue effects in order to better understand if or how they are related to the 
physical and biological properties of proton radiotherapy. 
 
1.7. Scope of Dissertation 
The RBE of protons for radiotherapy is traditionally assigned a constant, average value of 
1.1; however, the actual RBE of protons varies over the deposited dose distribution based on 
various factors, including proton energy, LET, dose per treatment fraction, number of treatment 
fractions, tissue and cell type specific factors, and biological and clinical endpoints.  It is 
plausible that the use of an average RBE value may lead to unexpected areas of higher effective 
dose and subsequent normal tissue toxicity.  Variability in RBE may be accounted for by 
incorporating a model that applies an RBE value determined by the factors specific to each point 
in the patient dose calculation grid.  This model may assume many forms, and indeed many 
models have been previously published.  It is important to remember, though, that the tissue 
specific biological factors incorporated into such models are inherently prone to uncertainty due 
to the limited amount of in vitro and in vivo data available, a fact which must be considered 
when evaluating biologically weighted treatment plans.  Despite the current limitations, it will 
be increasingly important to identify strategies in which the growing knowledge of proton RBE 
may be utilized to improve the standard of care in proton therapy.  The central hypothesis of 
this work is that radiation-induced imaging changes in the brain and brainstem resulting 
from proton radiotherapy are associated with the variable biological effectiveness of 
protons.  The hypothesis is tested for a cohort of pediatric patients treated for ependymoma 
who subsequently presented with radiation-induced imaging changes on post-treatment scans.  
The means of testing this hypothesis are encompassed by the following specific aims. 
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Specific Aim 1: To determine if the predictions of current RBE models are consistent with 
the results of high-throughput, high-resolution in vitro proton irradiation cell survival 
experiments.  Radiobiological modeling is performed for the results of cell survival experiments 
conducted with a high-resolution experimental system developed at the UT MD Anderson 
Cancer Center.  Models and experimental results are compared to assess the accuracy of the 
models for the system.  A new model is proposed when the current models are unable to 
adequately predict the results. 
Specific Aim 2:  To determine if there is a clinically significant difference between RBE-
weighted proton treatment plan dose distributions calculated using different RBE models.  A 
collection of current proton RBE models are incorporated into an in-house Monte Carlo dose 
calculation framework.  For a collection of treatment plans, this provides un-weighted dose, 
track-averaged linear energy transfer, and RBE and RWDs from multiple models on a voxel-by-
voxel basis.  Dose distributions determined with each model are evaluated for differences and 
any trends noted over a collection of patients.  The best model for further analysis is identified. 
Specific Aim 3:  To determine if the spatial location of proton radiation induced imaging 
changes is associated with the variable biological effectiveness of proton radiotherapy. For a 
cohort of pediatric ependymoma patients treated with passive scattering proton therapy, Monte 
Carlo calculated treatment plans incorporating metrics describing variable proton biological 
effectiveness are analyzed.  Treatment plans for patients presenting with radiation-induced post-
treatment imaging changes are compared against those of patients without imaging changes to 
determine if changes are associated with variable biological effectiveness.  A practicing 
radiation oncologist identified and contoured regions of image change on treatment planning 
computed tomography (CT) images using co-registered post-treatment MRI sequences.  The 
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image change contours are used to determine if the spatial location of changes coincides with 
increased variable biological effectiveness as opposed to constant biological effectiveness. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
20 
 
Chapter 2: Comparison of Experimental Results and RBE Models 
 
2.1. Motivation 
Specific Aim 1: To determine if the predictions of current RBE models are consistent with 
the results of high-throughput, high-resolution in vitro proton irradiation cell survival 
experiments.   
As has been previously discussed, there are many published models for proton RBE.  Some 
of them are based on differing approaches to fitting similar experimental data, while others are 
based on different approaches altogether to representing the biological effects of protons.  Due 
to these differences, the models provide different predictions of proton RBE and it is thus 
worthwhile to quantify how effective they are in modeling what is considered to be highly 
accurate experimental data.   
The proton biological effects research group at MD Anderson has produced a robust dataset 
that provides high-resolution data for RBE as a function of LETd
19.  Most previously published 
experimental RBE datasets have been based on measurements in SOBPs.  The energy spectrum 
of protons in an SOBP is generally rather broad and much less sharp than the spectrum that 
would be observed in a pristine Bragg peak19.  As a result, the previous experiments are more 
relatable to average LETd values as opposed to a single LETd value.  While the LETd value at a 
given point in a pristine Bragg peak is still an average, the reduced width of the energy spectrum 
is considered to provide a more accurate representation of the RBE for a given LETd. 
The goal of the analysis here is to apply the published RBE models previously discussed to 
determine if their predictions are still valid for high-resolution RBE data based on 
measurements in pristine Bragg peaks.  Invariably, the published models have provided for a 
linear increase of RBE with LETd.  The published RBE data from the MD Anderson group’s 
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experiments exhibit a non-linear increase in RBE particularly for LETd values above ~10 keV 
μm-1 19.  In order to properly account for this difference in the high LET region moving forward, 
a new model will be fit that is nonlinear in design while at the same time being scaled based on 
the (𝛼/𝛽)𝑥 to account for the inherent differences in biological response of different cell lines. 
 
2.2. Methodology 
2.2.1. MD Anderson Experimental Data 
In an effort to better define proton RBE for various levels of proton LET, the group at MD 
Anderson designed an experiment in order to measure cell survival for different levels of dose 
and LET for an “IMPT-like” beam.  The experimental setup has been described in detail in the 
publication by Guan and Bronk et al.19  The design consisted of a stepped compensator made of 
Lucite, which was placed in the path of the beam proximal to a 96-well plate.  The proton gantry 
was placed in the 180º position, i.e. below the compensator and plate with the beam directed 
upward.  The result of this setup was that the different columns of the 96-well plate were 
irradiated with different parts of the Bragg curve and thus encountered different levels of dose 
and LET.  The relative dose and LET values for each column of the 96-well plate are presented 
in Figure 2.   
After irradiation the samples were processed in order to produce cell survival curves based 
on the clonogenic survival assay.  The experimental data presented for this work consisted of 
two repeat experiments with the H460 cell line and also two repeat experiments with the H1437  
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Figure 2: Dose and LETd for the high-throughput experiment performed at UT MD 
Anderson Cancer Center. 
Dose and LETd in each of the 12 columns of the 96-well plate for the high-throughput 
clonogenic survival experiments performed at UT MD Anderson Cancer Center.  Dose and 
energy spectra data were calculated by Fada Guan, Ph.D., using the Geant4 Monte Carlo code19. 
 
cell line.  Both lines are non-small cell lung cancer cell lines.  Experiments were performed by 
Lawrence Bronk at the Proton Therapy Center – Houston19.  A reference data set was produced 
by irradiating the cell lines with Cs-137 photons.  The survival curves for the photon irradiation 
were used in the determination of RBE of protons compared to photons.  For this work, LETd 
values were calculated according to Equation ( 2 ) in which the LET is a dose-averaged 
quantity.  In order to calculate the RBE values, the survival curves were fit using the LQ model 
(Equation ( 5 )) to obtain the α and β values for each of the different proton LETd values for 
which measurements were performed.  Equivalent photon and proton doses required to achieve 
a SF of 10% were then calculated for each measurement point.  This allowed for the generation 
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of proton α and β values as a function of LETd as well as RBE for 10% SF as a function of LETd 
for both H460 and H1437 cell lines. 
 
2.2.2. Variable RBE model implementation 
Six previously published models for variable proton RBE were selected for comparison in 
this study.  These include the models by Wilkens and Oelfke22, Wedenberg et al.25, Carabe-
Fernandez et al.27,28,31, McNamara et al.32, Chen and Ahmad26, and the RMF model23,24,29,33. All 
of the models can be represented by the same basic LQ relationship represented by Equation ( 9 
).  The parameterizations of each of the different models in terms of RBEmax and RBEmin were 
previously presented in Table 1 and Table 2, respectively.  All of the models are based on 
LETd, which was calculated according to Equation ( 2 ) presented in Section 1.4 using proton 
energy spectrum data obtained through Geant4 Monte Carlo calculations performed by Fada 
Guan, Ph.D19.  As described in Section 2.2.1, reference photon αx and βx values were 
determined by fitting of Cs-137 clonogenic survival experiment results.  These values were then 
incorporated into the RBE calculation. 
An additional parameter was required for the calculation of RBE with the model by Wilkens 
and Oelfke.  The parameter λ, the LET scaling term, was determined according to the method 
described by Frese et al. in which αx, βx, the average target dose per fraction and the average 
target LETd were used to calculate the λ value necessary to achieve an average RBE of 1.1 in 
the target.  Equation ( 29 ) describes this method 
 
𝜆1.1 =
𝛼𝑥(𝑅𝐵𝐸 − 1) + 𝛽𝑥?̅?(𝑅𝐵𝐸
2 − 1)
?̅? − 0.5 𝑘𝑒𝑉/𝜇𝑚
 ( 29 ) 
where ?̅? is the average dose per fraction in the target and ?̅? is the average LET30.  Based on the 
experimental data, λ was calculated to be 0.02 µm keV-1 Gy-1 for a dose of 3 Gy, corresponding  
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Table 3: Values for RBEDSB and ?̅?𝑭 obtained from dose averaging of proton energy spectra 
for cell survival experiment LETd values. 
Dose-averaged RBEDSB and 𝑧?̅? (frequency mean specific energy) are presented for each of the 
LETd values for which measurements were made in the high-resolution cell survival 
experiments. 
LETd (keV µm
-1) RBEDSB 𝑧?̅? (Gy) 
0.94 1.02 0.008 
1.19 1.02 0.010 
1.74 1.04 0.014 
1.93 1.05 0.016 
2.04 1.05 0.017 
2.48 1.06 0.020 
3.26 1.09 0.027 
4.71 1.13 0.038 
10.7 1.34 0.086 
15.4 1.49 0.123 
17.9 1.57 0.142 
19.4 1.62 0.153 
 
 
to 10% SF, for LETd of 4.7 keV µm
-1 so that an RBE of 1.1 was achieved at this point.  This 
point was selected to provide acceptable matching to the experimental data. 
In order to calculate RBE based on the RMF model, proton energy spectra for each LETd 
value were used to dose average the quantities RBEDSB and 𝑧?̅?.  Dose averaging was performed 
in a manner similar to that presented for LET in Equation ( 2 ).  In this case RBEDSB(E) or  
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Table 4: Fitted αx and βx parameters and ratios based on Cs-137 cell survival experiments. 
LQ model parameters for the H460 and H1437 cell lines obtained from fitting with the LQ 
model are presented.  Standard deviations are included in parentheses. 
Cell Line 𝜶𝒙 𝜷𝒙 (𝜶/𝜷)𝒙 
H460 0.36 (± 0.03) 0.071 (± 0.008) 5.1 (± 0.7) 
H1437 0.08 (± 0.03) 0.031 (± 0.005) 3 (± 1) 
 
 
𝑧?̅?(𝐸) was substituted for 𝑆𝑒𝑙(𝐸) in the numerator.  A Σx value of 8.3 DSB Gy
-1 Gbp-1 for Cs-
137 γ-rays was utilized for the calculation of RBEDSB.  The obtained values used for RBE 
calculation are presented in Table 3. 
 
2.2.3. Fitting a new RBE model based on MD Anderson experimental data 
Given the non-linear increase of RBE with LETd in the MD Anderson experimental results, 
a new variable RBE model was also fit to the data.  The approach taken for fitting the model 
was similar to that seen in previous publications in that the ratio 𝛼/𝛼𝑥 and √𝛽/𝛽𝑥 were fit as 
functions of LETd with dependence on (𝛼/𝛽)𝑥 to provide additional scaling based on the 
inherent biological properties of different cell lines.  The polynomial form chosen for fitting was 
that of the cubic function due to the substantial non-linear increase in the ratios for the highest 
LET values as observed in the study by Guan and Bronk et al.19  Fitting was performed using 
the nonlinear regression toolbox of OriginLab 8.6 (OriginLab Corporation, Northampton, MA). 
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2.3. Results 
Based on the fitting of the Cs-137 clonogenic survival data, αx and βx values for both the 
H460 and H1437 cell lines were determined.  These values are presented in Table 4 and they 
have further been incorporated into calculations of RBE.  Fitting of survival data for proton 
experiments produced α and β values for each of the 12 LETd values at which measurements 
were performed.  The ratios 𝛼/𝛼𝑥 and √𝛽/𝛽𝑥 (RBEmax and RBEmin, respectively) for each LETd 
value are presented in Figure 3.  Along with the ratios, the fitted curves of the data are 
presented, which constitute the RBEmax and RBEmin components of the proposed RBE model.  
The equation for RBEmax is of the form 
 
𝑅𝐵𝐸𝑚𝑎𝑥 =
𝛼
𝛼𝑥
= 0.75 +
0.00143
(𝛼/𝛽)𝑥
𝐿𝐸𝑇𝑑
3 
( 30 ) 
where the scaling term for LETd is inversely proportional to (𝛼/𝛽)𝑥 and the function scales with 
the cube of LETd.  The function for RBEmin is of a similar form 
 
𝑅𝐵𝐸𝑚𝑖𝑛 =  √
𝛽
𝛽𝑥
= 1.24 + 0.00074 (𝛼/𝛽)𝑥 𝐿𝐸𝑇𝑑
3 ( 31 ) 
where the scaling term for LETd is directly proportional to  (𝛼/𝛽)𝑥. 
Figure 4 presents the comparison of seven RBE model predictions to the experimental RBE 
values for two experiments with H460 and two experiments with H1437.  RBE is calculated at 
the 10% SF level.  Most of the previously published models agree well with the experimental 
results up to an LET value of approximately 10 keV μm-1.  As a result of the fitting of the data, 
the new model provides a better prediction of the results beyond 10 keV μm-1.  The new model  
also displays an ability to account for the biological differences in the two cell lines due to its 
dependence on their photon biological parameters. 
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Figure 3: Fitting of the ratios 𝜶/𝜶𝒙 and √𝜷/𝜷𝒙 as functions of LETd for both the H460 
and H1437 cell line experimental results. 
The ratios (A) 𝛼/𝛼𝑥 and (B) √𝛽/𝛽𝑥 are presented for the H460 (red dots) and H1437 (black 
dots) experimental data.  Fits of the ratios as cubic functions of LETd are also presented. 
28 
 
 
Figure 4: Comparison of measured and model calculated (including new model fit) RBE 
vs. LETd for both the H460 and H1437 cell lines. 
Predicted RBE values from seven models (Wilkens and Oelfke22, Wedenberg et al.25, Carabe-
Fernandez et al.27,28,31, McNamara et al.32, Chen and Ahmad26, RMF23,24,29,33, and the new model 
from this work (Peeler)) are compared to the experimental results for both the (A) H460 and (B) 
H1437 cell lines. 
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2.4. Conclusions 
Results from clonogenic survival experiments performed at MD Anderson and the 
predictions of seven RBE models, including a new model created specifically for this study, 
have been compared.  While the non-linear nature of the relationship between RBE and 
increasing LET was unexpected, the inability of currently published models of variable proton 
RBE to adequately predict these results was to be expected after observation of the experimental 
results.  All of the currently published models generally predict a linear increase of RBE with 
increasing LETd.  This relationship of course originates from the data upon which the various 
models were fit.  In some cases datasets with very large spreads in observed RBE values were 
used for fitting with the assumption that a linear fit of the data was the most reasonable 
approach.  For this particular set of data, obtained with pristine monoenergetic beams, repeat 
experiments with two cell lines have shown that a non-linear increase of RBE with LET is 
reproducible with great consistency. 
There are many potential reasons for the observed results.  One of the most probable 
explanations can be attributed to the design of this experiment compared to the experiments 
upon which the published RBE models are primarily based.  Previous cell survival experiments 
have, for the most part, been performed with spread-out proton Bragg peaks.  In the creation of 
an SOBP, the spectrum of LET values of protons at a given depth becomes more muddled and 
spread out.  This could potentially lead to a decrease in the effectiveness of the proton radiation 
as the average LET value would now be a result of many LET values with differing 
effectiveness.  In the MD Anderson experiment, it was shown that the spectrum of LET values 
represented by the average LET in each column of the well plate was actually quite narrow, at 
the very least more narrow than what would be observed in an SOBP19. 
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The overall conclusions to be drawn for this aim are that current RBE models may not be 
adequate for predicting experimental results for narrow LET spectra, particularly in the high 
LET region of the proton Bragg peak.  A new model based on an empirical fit of the 
experimental results has been developed and will thus be carried through for analysis in patient 
treatment plans in Specific Aim 2 of this study. 
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Chapter 3: Comparison of RBE Models for Treatment Plans 
 
3.1. Motivation 
Specific Aim 2: To determine if there is a clinically significant difference between RBE-
weighted proton treatment plan dose distributions calculated using different RBE models.   
It has now been shown that published RBE models cannot adequately predict RBE for high 
LETd as measured from high-resolution experiments.  This is particularly the case for LETd 
values above 10 keV μm-1.  While this is obviously relevant in the experimental setting, it is 
important to determine the relevance of such differences within the scope of patient treatment 
plans, which constitute different proton energy spectra and different values of LETd.  Toward 
this objective, the RBE models will be implemented in a system for calculating patient treatment 
plans.   
One of the key components for calculating RBE is LET; however, the commercial treatment 
planning system (TPS) employed at MD Anderson does not have the capability to compute LET 
values for clinical treatment plans.  This data is necessary in order to calculate RBE, so it must 
thus be obtained by some other method.  The primary method employed for calculating accurate 
dose and LET for protons and other ions is known as the Monte Carlo method.  This is a 
computing technique in which the interactions of single particles may be simulated from their 
creation until all of their energy has been deposited.  This process is repeated hundreds, 
thousands, or millions of times until an average distribution of acceptable statistical accuracy is 
obtained.  This method will be employed here for the purpose of obtaining dose and LET for the 
treatment plans of the cohort of interest that was previously identified in Section 1.6.  The data 
will then be utilized to calculate RBE and RWD for seven RBE models.  The results will then be 
compared to determine if any single model provides the greatest difference between constant 
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and variable RBE-weighted dose.  The identified model will be carried forward for the analysis 
of outcomes for the patient cohort in Chapter 4. 
 
3.2. Methodology 
3.2.1. Treatment Plans of Interest 
Thirty-four pediatric ependymoma patients treated with protons were selected for analysis in 
this study.  These patients were treated as part of the prospective protocol of normal tissue 
toxicity with proton therapy that was examined in the study by Gunther et al.58.  All patients 
were treated with PSPT with the exception of one patient who received an IMPT boost plan.  
Patient treatments consisted of a primary plan and one or two boost plans.  Dose prescriptions 
were between 54 and 59.4 Gy in 1.8 Gy fractions.  In terms of treatment plan design, only the 
characteristics of the delivered dose are of interest for this analysis. 
 
3.2.2. Computing Treatment Plans with MCNPX 
  For the purposes of this study, the Monte Carlo method is employed to calculate dose and 
the LET for treatment plans of interest.  An in-house system known as MC2, based on the Monte 
Carlo code MCNPX59, is employed for this purpose.  The system is designed to accept patient 
treatment plan information in a standard format called Digital Imaging and Communications in 
Medicine (DICOM).  A C++ program reads this information and converts it into input files 
acceptable by the MCNPX program.   
As an example, for PSPT treatment plans, this involves the creation of a digital model of the 
proton treatment delivery system, assigning the specific proton energies employed in the 
treatment plan, creating an MCNPX-compatible representation of the patient geometry 
(obtained from the patient’s planning CT images), and specifying which data is to be collected 
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and in what region.  For PSPT plans, a separate file is created for each energy of the proton 
beam used to create the SOBP.  For each file, the MCNPX simulation is run for millions of 
particles.  Once all of the simulations have been completed, the collected data is combined 
according to weighting factors assigned to each energy obtained from the DICOM plan file.  
Based on the specific components of the treatment delivery snout utilized in a particular 
treatment plan, the number of protons used for the simulations is converted into monitor units 
(MUs) and then scaled based on the actual number of MUs delivered to the patient.  The 
MCNPX code is specifically used to obtain energy deposition data, which can be converted 
directly to dose, and the total proton fluence in each sub-volume, or voxel, of the patient 
treatment plan.  This information can be used to calculate LETt according to Equation ( 1 ), 
since this operation is effectively the total dose divided by the total fluence. 
While most studies have been based on LETd, the LETt is an acceptable approximation for 
LETd for lower values of LET, such as those encountered in most patient treatment plans.  LETt 
has been shown to be linearly proportional to LETd in this low LET region
12.  Many of the 
patient treatment plans consisted of a primary plan and one to two boost plans.  As such, the 
dose and LET values used are sum and average values, respectively, over all plans for a given 
patient. 
 
3.2.3. Computing Variable RBE with MC data 
The MC2 system currently does not have any built-in functionality to perform RBE 
calculations based on the simulation output.  This operation is thus performed using Matlab 
2014b (The MathWorks, Inc., Natick, MA) due to its inherent advantages in working with 
matrix-based data.  The seven RBE models employed in the analysis in Chapter 2 were also 
implemented in the Matlab treatment plan RBE calculation infrastructure.  For the purpose of  
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Table 5: αx and βx parameters and ratios for normal tissues of interest. 
LQ model parameters for the brain and brainstem obtained from Frese et al.30  The endpoint of 
relevance for the presented tissues is necrosis/infarction. 
Tissue Endpoint 𝜶𝒙 (Gy
-1) 𝜷𝒙 (Gy
-2) (𝜶/𝜷)𝒙 (Gy) 
Brain/Temporal 
lobes 
Necrosis/infarction 0.0620 0.0310 2 
Brain stem Necrosis/infarction 0.0532 0.0266 2 
 
 
this study, RBE was calculated according to LETt, which was in turn calculated as an average 
value over all treatment beams and plans for a given patient. 
Because most of the models are empirical fits of measured data, their implementation was 
straightforward; however, for the RMF model, which is semi-mechanistic, additional data was 
needed for calculation.  The MCDS24,40–43 software was used to obtain data for DSB Gy-1 Gbp-1 
for a range of proton energies relevant to that which would be encountered in treatment plans.  
Using a reference value of 8.3 DSB Gy-1 Gbp-1 for Co-60 γ-rays, RBEDSB was calculated for the 
spectrum of proton energies.  The data was fit with a quadratic function resulting in Equation ( 
32 ). 
 𝑅𝐵𝐸𝐷𝑆𝐵 = 0.0011 ∗ 𝐿𝐸𝑇
2 + 0.0394 ∗ 𝐿𝐸𝑇 + 0.9707 ( 32 ) 
Similarly, data for 𝑧?̅? was also collected for the range of energies and fit with a linear function 
represented by Equation ( 33 ). 
 𝑧?̅? = 0.0131 ∗ 𝐿𝐸𝑇 + 0.0088 ( 33 ) 
These steps were necessary as these pieces of information could not be dose-averaged on a 
voxel-by-voxel basis because the full proton energy spectrum was not produced by MCNPX. 
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Normal tissue effects in the brain and brainstem are of particular interest for this study, so 
RBE was calculated based on these structures only.  The biological parameters for photons for 
the brain and brainstem were obtained from a study by Frese et al.30  Table 5 displays the values 
for αx, βx, and (𝛼/𝛽)𝑥 for both brain and brainstem that were utilized for RBE calculation.  The 
value for the Wilkens and Oelfke22 model parameter λ used for RBE calculation was also taken 
from the study by Frese et al.30 but rounded to be 0.01 µm keV-1 Gy-1. 
 
3.2.4. Comparison of Constant and Variable RWD for Treatment Plans 
For the previously identified patient cohort of interest, constant and variable RBE-weighted 
total plan doses were computed for all patients.  Mean and max constant RBE-weighted dose, 
variable RBE and variable RBE-weighted dose, and LETt for the clinical target volume (CTV), 
brain, and brainstem were computed.  Difference between mean constant RBE-weighted dose 
and variable RBE-weighted dose for all RBE models for all patients was compared using a two-
sided paired t-test of difference.  Mean difference, standard deviation, and significance of the 
test are reported for all models. 
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Figure 5:  TPS and MC dose and dose differences for an example treatment plan. 
Constant RWD from the (A) TPS and (B) MC simulations are presented.  The difference 
between TPS and MC doses distributions (TPS dose - MC dose) is presented in panel (C).  
Structure contours for brain (orange), brain stem (black), and the CTV (blue) are included. 
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3.3. Results 
Examples of TPS dose, MC dose, and their difference for a single patient are presented in 
Figure 5A, Figure 5B, and Figure 5C, respectively .  For this example beams are impinging 
from the lateral directions and the greatest differences between the TPS and MC doses are in the 
regions near the lateral edges and end of range of the beams.  Observed differences are on the 
order of approximately 5 Gy with the MC simulations predicting lower dose. 
An additional example comparing MC calculated constant RWD and variable RWD 
calculated according to the McNamara et al.32 model is presented in Figure 6.  The 
corresponding LETt distribution is included in Figure 6C.  As expected, the variable RWD is 
observed to be greater in the distal edge and distal falloff regions of the beams, which is 
represented in Figure 6D. 
The results of the collected analysis of the differences between variable and constant RBE-
weighted dose are presented in Table 6.  Despite the small number of patients analyzed (34 in 
total), all of the models are observed to produce significantly different mean CTV doses 
according to a two-sided paired difference test.  The model by Chen and Ahmad provides the 
greatest differences; however, the difference is so great that it may likely be attributed to 
improper scaling of the model for different cell lines.  The model displaying the next greatest 
difference is that by McNamara et al.32 which shows a 7.2% increase in variable RBE-weighted 
dose over constant RBE-weighted dose. 
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Figure 6: Constant RWD, variable RWD, LETt, and the difference between variable and 
constant RWD for an example treatment plan. 
MC calculated (A) constant RWD and (B) variable RWD are presented.  The corresponding MC 
calculated LETt distribution is displayed in panel (C).  The difference between variable RWD 
and constant RWD (variable – constant) is presented in panel (D).  Structure contours for brain 
(orange), brain stem (black), and the CTV (blue) are included. 
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Table 6: Comparisons of Mean CTV variable and constant RWD for multiple RBE 
models. 
The differences between mean variable RWD and constant RWD in the CTV over 34 patients 
for seven RBE models are presented.  The models include those by Wilkens and Oelfke22, 
Wedenberg et al.25, Carabe-Fernandez et al.27,28,31, McNamara et al.32, and Chen and Ahmad26, 
as well as the RMF23,24,29,33 model and the model developed for this work (Peeler). A two-sided 
paired difference test was performed to determine significance. P values were evaluated at the 
0.05 significance level.  Mean differences as a percent of the mean constant RWD are also 
included. 
RBE Model 
Mean Difference: 
Variable - 
Constant RBE 
Dose(Gy) 
StDev 
P-value (Null: 
Mean = 0) 
Difference as 
% of Constant 
RBE Dose 
Wilkens and Oelfke -1.2 0.8 6.7E-05 2.1 
Wedenberg et al. 1.9 0.9 1.7E-06 3.3 
Carabe-Fernandez et al. 2.0 0.8 5.2E-07 3.6 
McNamara et al. 4.1 0.7 1.4E-11 7.2 
Chen and Ahmad 20.3 2.9 1.4E-12 35.8 
RMF -2.3 0.6 1.5E-09 4.0 
Peeler -2.3 0.2 2.3E-16 4.0 
     
 
3.4. Conclusions 
Comparison of constant RWD between the TPS and MC system revealed that the systems 
do have differences in their calculations of proton dose distributions evidenced by lower MC 
calculated dose in the distal and lateral edges of the proton beams compared to the TPS.  This is 
observable in Figure 5C.  These differences can be sourced to a number of factors arising from 
the inherent differences between TPS and MC dose calculation.  The TPS calculates dose by 
converting pre-measured or pre-calculated proton depth dose distributions into an analytical 
40 
 
function which is then used to calculate dose on the patient geometry.  This method cannot fully 
account for energy straggling and lateral scattering effects which are modeled in the MC physics 
calculations60,61.  These effects can lead to lower MC calculated dose in the distal and lateral 
edges62,63.  It has been observed that this degradation of the distal edge of proton beams is often 
not adequately modeled by the TPS dose calculations, particularly in heterogeneous 
materials62,64–66.  TPS analytical algorithms have also been shown to approximate the way in 
which the proton beam shines on the range modulator in PSPT, resulting in overestimation of 
the dose on the proximal edge of the SOBP67, which can result in a further reduction in dose 
when the proximal edge of a beam overlaps with the distal edge of another beam..  Additionally, 
the methods by which the two systems account for material densities are different.  The TPS 
determines electron density directly through CT numbers from the planning CT, while for the 
MC simulation the planning CT is converted into specific material specifications in the input 
file.  Differences in material density between the two systems could lead to differences in 
calculated dose.  In general, the differences between the systems were on the order of 5 Gy and, 
importantly, were not observed in the region of the CTV, which was used for analysis here. 
This specific aim has resulted in the capability for calculating variable RWDs for seven 
RBE models based on the output data of the MC2 system.  Analysis of the results for a cohort of 
patients has shown that differences in mean values for variable RWD compared to constant 
RWD in the CTV structure are significant for all of the analyzed RBE models.  In particular the 
models by Wedenberg et al.25, Carabe-Fernandez et al.27,28,31, and McNamara et al.32, and Chen 
and Ahmad26 provide increases over the constant RWD, while the model by Wilkens and 
Oelfke22, my own model, and the RMF model23,24,29,33 show decreases in mean CTV dose.  The 
results produced by the model from Chen and Ahmad26 appear to be outlier values, but this is to 
be somewhat expected since the model was fit for specific cell line with no inherent scaling 
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mechanism for different cell lines.  Of the models providing an increased variable RWD 
compared to constant RWD, the model by McNamara et al.32 exhibits the greatest difference 
that would not be attributed to potentially erroneous values (i.e. the Chen and Ahmad model26).  
The McNamara et al.32 model will thus be carried forward for the analysis performed in Specific 
Aim 3. 
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Chapter 4: Assessing the Role of Variable Proton Biological 
Effectiveness in Observed Treatment Outcomes 
 
4.1. Motivation 
Specific Aim 3: To determine if the spatial location of proton radiation induced imaging 
changes is associated with the variable biological effectiveness of proton radiotherapy. 
While laboratory studies suggest increased biological effectiveness near the end of proton 
beams, to date there is little evidence to suggest that such changes are important clinically.  
Initial studies have looked for clinical evidence of increased biologic effectiveness with mixed 
results20. This may be in part due to the fact that such studies have looked to map proton RBE as 
a function of dose and LET (and sometimes other factors) using models based on in vitro 
experiments performed with various cancer cell lines11,19,20,32,68.  Such models, typically 
involving measures of clonogenic survival, may not be applicable to complex in vivo processes 
including multiple cell types, such as radiation-induced brain damage. The apparent lack of 
evidence may also be due to multiple other sources of uncertainties that may obscure 
consequences of approximation in RBE. 
In the realm of photon therapy, the appropriate safe and effective doses for treating various 
types of tumors and the tolerance doses for normal tissues have been derived from the collected 
analysis of decades of patient outcomes data50,69–71.  When assessing a newer technology such as 
proton therapy, it would make sense to take a similar approach to develop such knowledge. 
However, because of the limited availability of proton therapy, patient data is limited; yet given 
its high cost, there is pressure to fully elucidate the benefit of proton therapy72–74.  
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Gunther et al. recently identified that, in comparison to patients treated with photon therapy, 
children with ependymoma treated with protons more frequently developed post treatment MR 
imaging changes in normal brain parenchyma58.  Such changes in imaging biomarkers are 
considered a grade 1 toxicity and although many patients will not develop clinical symptoms, 
such imaging changes are important for studying the biological properties of protons as a 
function of dose and LET. While clinical factors, such as age, may account for some difference, 
this study seeks to analyze patients treated with protons to determine if the location of post-
treatment image changes are related to physical proton characteristics, more specifically LET.  
By looking at voxel-level data rather than only volume-based data, this study seeks to improve 
the ability to correlate clinical imaging data with dose and LET.  
 
4.2. Methodology 
4.2.1. Patient Cohort and Image Processing 
The same 34 pediatric ependymoma patients treated with protons from the Gunter et al. 
study are again analyzed here.  A subset of 14 patients exhibited post-treatment MR imaging 
changes observable as T2-FLAIR hyperintensity with or without enhancement on T1 post-
contrast sequences.  MR images were rigidly registered with treatment planning CT images 
using the Eclipse treatment planning system (TPS) v9.0 (Varian Medical Systems, Inc., Palo 
Alto, CA).  Regions of treatment-related change in normal brain parenchyma were contoured by 
a practicing radiation oncologist based on the earliest post-treatment scan in which image 
changes were observed. 
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4.2.2. Voxel-level Analysis of Image Changes 
In order to prevent fracturing and reducing the size of the data set, all image changes were 
evaluated as being within the whole brain.  The contoured image change regions were identified 
with voxels represented as binary response (image change) 1 while voxels within the brain 
outside of the response region were represented as response 0.  Combined with the dose and 
LETt data, this produced over eight million ‘events,’ each with its corresponding dose, LET, and 
image change status (0 or 1).  Voxel data points with dose below 1 Gy were then removed from 
the dataset because these points were effectively noise and no image change would be expected 
to be observed at this dose.  Using the Matlab 2014b glmfit function, a generalized linear model 
fit of the data was performed according to the binomial distribution with a probit link function.  
Dose and LET were taken to be the predictors in the model.  The probit model assumed in the 
fitting is the normalized cumulative distribution function with µ = 0 and the standard deviation σ 
= 1, which results in the same general probit model utilized by Lyman for NTCP calculation 
represented by Equation ( 26 )48.  In this case 𝑃 is the probability of image change.  The result 
of the fitting is a set of coefficients for a linear function of dose and LET, which is represented 
by the variable 𝑐 in Equation ( 26 ). 
 
4.2.3. Statistical Analysis 
A set of 10 clinical and treatment factors were selected for logistic regression analysis to 
determine if there was any association with the presence of image changes.  Of the clinical 
factors analyzed in the paper by Gunther et al., age at radiotherapy and time before radiotherapy 
(after surgery) were selected for inclusion in this analysis due to their trends toward significance 
in that study58.  The other eight factors selected for this study include mean and maximum LET, 
mean and maximum physical dose, mean and maximum variable RBE, and mean and maximum 
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variable RBE-weighted dose in the CTV.  RBE values were calculated using the model by 
McNamara et al.32  Univariate and multivariate logistic regression analysis was performed using 
Matlab 2014b in order to determine if any were significantly associated with the presence of 
image changes.  Odds ratios and 95% confidence intervals (CI) were calculated for each factor.  
Factors with p value less than 0.25 on univariate analysis were included in the multivariate 
analysis.  No interaction variables were included in the multivariate analysis. 
      Leave-one-out cross validation (LOOCV) was performed in order to test the robustness 
of the fitted generalized linear model.  For this dataset, which consists of a very large number of 
voxels, traditional LOOCV would not provide a reasonable assessment of the model.  The cross 
validation was performed by successively leaving out all of the voxels from each individual 
patient with image changes and then testing the model on the left out set of voxels.  The data 
from the patients without image changes was included in each of the training datasets and 
effectively served as additional control data for no image change.  Model parameters were 
calculated for each of the 14 left-out patients.  For each iteration, a receiver operating 
characteristic (ROC) curve was produced and the area under the curve (AUC) was calculated 
using the Matlab perfcurve function.  This could not be performed for the patients without 
changes because there would be no true positive cases in the test dataset.  This is yet another 
reason why this data was simply included in all of the training datasets. 
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Table 7: Univariate and multivariate logistic regression analysis on clinical factors for all 
patients. 
Results of univariate logistic regression analysis are presented for 10 clinical and treatment 
factors for the 34 patients of interest.  Binary classifiers were determined based on mean values 
over all patients.  Four factors with p-value < 0.25 on univariate analysis were also included in 
multivariate logistic regression analysis. 
Variable 
Odds 
Ratio 
  95% CI   
P Value - 
Univariate 
  
P Value - 
Multivariate 
Mean LET in CTV        
> 1.5 keV µm-1 8.67  0.94 - 80.0  0.06  0.63 
Max LET in CTV        
> 2.5 keV µm-1 7.33  1.29 - 41.7  0.02  0.53 
Mean CTV physical dose        
> 52 Gy 0.61  0.15 - 2.43  0.49   
Max CTV physical dose        
> 56 Gy 0.82  0.21 - 3.22  0.77   
Mean CTV RBE        
> 1.16 0.44  0.10 - 1.92  0.28   
Max CTV RBE        
> 1.22 0.92  0.23 - 3.63  0.90   
Mean CTV RWD        
> 61 Gy(RBE) 0.50  0.13 - 2.00  0.33   
Max CTV RWD        
> 65 Gy(RBE) 1.00  0.26 - 3.92  1.00   
Age at RT        
< 3 years 2.50  0.58 - 10.7  0.22  0.65 
Time before RT        
< 3 Months 7.00  0.75 - 65.2  0.09  0.30 
New abbreviations: RT = radiotherapy 
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Figure 7: Surface plot of generalized linear model for image change based on dose and 
LETt. 
Three-dimensional representation of the fitted generalized linear model that predicts probability 
of image change in a voxel as a function of dose and LETt.  The faded portion of the surface 
indicates the region above the maximum physical dose observed in the patient cohort (60 Gy).  
This region is extrapolated from the model.  The maximum LETt observed within the image 
change regions was 5 keV µm-1, thus the LETt axis is not further extrapolated in the figure. 
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4.3. Results 
A total of 10 clinical and treatment factors, which are presented in Table 7, were analyzed 
to determine any association with the presence of image changes.  Of the factors presented, only 
maximum LETt in the CTV was found to be significant (p = 0.02) at the 0.05 level on univariate 
logistic regression analysis.  Mean LET in the CTV (p = 0.06), age at radiotherapy (p = 0.22), 
and time before radiotherapy (p = 0.09) all presented p < 0.25 and were thus included in 
multivariate logistic regression analysis.  None of the factors were subsequently found to be 
significant at the 0.05 level on multivariate analysis. 
Figure 7 presents the results of fitting a generalized linear model for image change based on 
the dose and LET predictors.  The model was evaluated for a distribution of dose and LET 
values to produce the surface plot.  The faded region in Figure 7 indicates values that are 
extrapolated beyond the data used for the fitting of the model.  The reported model parameters 
are the result of cross-validation performed by fitting the model while successively leaving out 
each of the patients with image changes.   The generalized linear model is represented by the 
following equation 
 𝑐 = 1.2 ∗ 𝐿𝐸𝑇𝑡 + 0.14 ∗ 𝐷𝑜𝑠𝑒 − 11.2 ( 34 ) 
in which the coefficients are the mean values determined through cross validation.  The standard 
deviations of the LETt coefficient, dose coefficient, and intercept are 0.1, 0.01, and 0.7 
respectively.   
     In order to better visualize the relationship between image change, dose, and LETt for 
different values of dose and LETt, Figure 8A and Figure 8B display two-dimensional slices 
through the surface for constant LETt of 1, 2, 3, 4, and 5 keV µm
-1 and constant physical dose of 
30, 40, 50, 60, and 70 Gy, respectively.  It is further possible to extract more traditional values  
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Figure 8: 2-D representations of the generalized linear model for image change for 
constant LETt or physical dose. 
Curves represent slices through the 3-D surface produced by the generalized linear model for 
(A) constant LETt of 1, 2, 3, 4, and 5 keV µm
-1 and (B) constant physical dose of 30, 40, 50, 60, 
and 70 Gy. 
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for TD50, the tolerance dose at which a toxicity would be expected to be observed in 50% of 
patients, for different values of proton LETt.  This data is presented in Figure 9.  The TD50 data 
were fit with a linear equation (the expected result due to the generalized linear model fitting) 
which is represented by Equation ( 35 ). 
 𝑇𝐷50 = 80.0 − 8.57 ∗ 𝐿𝐸𝑇𝑡 ( 35 ) 
TD50 is observed to decrease with LETt, a trend which indicates an increase in biological 
effectiveness of proton dose with increasing LETt consistent with traditional RBE models for 
proton therapy. 
      A more practical representation of the model is presented in Figure 10.  Dose and LET 
distributions for an example patient are plotted on an axial CT slice in Figure 10A and Figure 
10B, respectively.  The LET distribution in the figure has an abrupt edge due to the size of the 
grid used for Monte Carlo calculations.  Dose and LET beyond this edge were not calculated 
because the region is out-of-field and limiting the size of the calculation grid allows for 
improved calculation efficiency.  The probability of image change is plotted in Figure 10C.  
Qualitatively the areas of increased probability of image change predicted by the model are 
observed to overlap with the region of image change indicated by the contour generated using 
the registered post-treatment MR image. 
      Cross validation of the model generated 14 ROC curves, one for each leave-out iteration.  
The cross-validated AUC for the model was 0.91 with a 95% confidence interval (CI) of 0.88 – 
0.94. 
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Figure 9: TD50 as a function of LETt based on interpolation of the generalized linear model 
for image change. 
Line displays the values for TD50 interpolated from the fitted generalized linear model for a 
range of LET values.  The solid portion of the line represents the range of data observed in the 
patient cohort, while the dashed line represents extrapolation from the generalized linear model.  
The equation for a linear fit of TD50 versus LET is also presented. 
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Figure 10: Dose, LETt, and probability of image change distributions for an example 
patient. 
Figure displays (A) physical dose and (B) LET distributions on an axial CT slice for an example 
patient.  Probability of image change calculated with the generalized linear model is presented 
in panel (C).  Structure contours include the image change region (red), brain (orange), brain 
stem (black), and CTV (blue). 
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4.4. Conclusions 
      As in the Gunther et al.58 study, the clinical factors age at radiotherapy and time before 
radiotherapy were found to trend toward significance on univariate analysis in this study; 
however, they were found to not be significant on multivariate analysis.  Unfortunately, these 
clinical factors cannot be overcome by the use of the voxel-level analysis since they are patient 
specific and thus modeling their impact is very much beholden to the number of patients in the 
study.  Simply including them as predictors in the generalized linear model is not viewed as an 
adequate consideration of their effect because there is no evidence to suggest that they would be 
best modeled linearly, unlike LET effects.  Analysis of more patient data may eventually allow 
for development of different models for different ranges of ages at treatment and time between 
surgery and radiation therapy. 
     Interestingly, the selected treatment factors related to dose and LET were not found to be 
significant on multivariate analysis.  This is not necessarily unexpected because the entire 
purpose of carrying out voxel-based data analysis was to overcome some of the inherent 
problems of point and volume-based analysis.  In this sense, given the results, the image 
changes observed can more likely be attributed to dose and LET distributions in certain sub-
volumes of tissue, which would be difficult to observe through whole organ volume or point 
based measures. 
This analysis has shown that voxel-based, post-treatment MR image changes in pediatric 
patients treated with proton therapy are dependent on both physical dose and LETt.  A 
generalized linear model based on a probit link function was developed which can describe the 
decrease in the TD50 for image change as proton LET increases.  The ROC curves describing the 
model’s ability to positively identify voxels with image change had a cross-validated AUC of 
0.91 (95% CI: 0.88-0.94).  To my knowledge, this is the first example of the extraction of 
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proton biological effectiveness information from clinical data.  The success of this study 
supports the continued investigation of proton therapy outcomes with the goal of identifying 
other quantifiable responses or toxicities that could be used to further the collective 
understanding of proton biological effectiveness in humans.  Models developed from this type 
of analysis could eventually be used prospectively to design safer and more effective proton 
treatments. 
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Chapter 5: General Discussion 
5.1. Summary and Discussion of Findings 
The central hypothesis of this work was that radiation-induced image changes observable on 
follow-up imaging could be attributed to the variable biological effectiveness of proton 
radiotherapy.  The approach taken to test this hypothesis first involved the identification of 
appropriate models for calculating the variable RBE of protons.  New high-resolution cell 
survival data produced by the MD Anderson proton therapy research group was utilized here for 
the purpose of testing the accuracy of the models on a more robust data set than those used for 
the creation of the models.  Comparison of the model output to the experimental data proved 
that the models cannot adequately reproduce the RBE for high LET protons measured from the 
experiments.  The models and experiments typically began to deviate in the region where LET 
was greater than 10 keV μm-1, which corresponds to the region of the proton Bragg peak and 
distal falloff.  A new model was fit based on the experimental results from the two analyzed cell 
lines, with consideration to the incorporation of the photon (𝛼/𝛽)𝑥 into the formalisms for 
RBEmin and RBEmax such that the resulting model might be more translatable to other 
experimental cell lines employed in the future. 
All of the selected RBE models and additionally the newly developed model were then 
implemented into a codified form that could be used to calculate RBE for patient treatment 
plans based on the output of Monte Carlo simulations.  Monte Carlo simulations were 
performed for a group of 34 patients treated on protocol with PSPT who were of interest due to 
their high rate of occurrence of post-treatment image changes observed on MRI.  For this step of 
the study, the variable RBE-weighted dose distributions from all models for all of the patients 
were compared in order to determine if any particular model could prove more useful in 
determining if the location of the image changes was related to RBE.  As a result of this 
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analysis, the RBE model by McNamara et al.32 was identified to produce the greatest positive 
difference, on average, between variable and constant RWD.  This comparison was performed 
for the CTV structure in particular due to the fact that many of the identified image changes 
occurred in-field.  While the model by Chen and Ahmad26 did actually produce the greatest 
difference in doses, it was decided that the predicted differences were unreasonably large, most 
likely due to the model’s lack of inherent scaling with the reference radiation alpha/beta ratio for 
a particular cell type.   
Comparison of average volumetric variable RWD values between patients presenting with 
image changes and those without showed no significant differences between the two groups.  
This result motivated a shift in approach such that voxel-based data would be analyzed instead 
of volumetric data.  Based on the probit dose-response relationship, which is traditional to 
radiation therapy outcomes analysis, a generalized linear model was fit according to all of the 
voxel-based data from the 34 patients of interest.  Using the image change data to define a 
binary response metric, the probability of response based on the developed model was observed 
to increase with LETt for a given physical proton dose.  Statistical analysis of the model output 
was performed through LOOCV.  The average AUC over the ROC curves calculated for each 
patient with image change was 0.91 (95% CI: 0.88-0.94) which is a high value, indicating that 
the model was robust for this data set and is more likely to be applicable to patients beyond this 
data set. 
Variable proton biological effectiveness is not currently incorporated into clinical treatment 
planning. This is due in large part to uncertainty in published RBE values and the apparent lack 
of clinical evidence that the use of a constant RBE value leads to suboptimal outcomes20.  This 
study aimed to tackle the latter point by providing evidence that post-treatment changes 
observed on follow-up imaging studies are associated not only with dose but also with LET.  In 
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pediatric ependymoma patients treated with proton therapy, I found significant correlations 
between spatial areas of image change and increasing LET. 
The analysis presented was made with a novel method, which incorporates voxel-level data 
to correlate imaging change with physical dose and LET data from the treatment plan.  This is a 
departure from the typical strategy of using whole organ volume-based data. I believe that my 
strategy is logical due to the nature of the response I am analyzing, i.e. to deduce the biological 
effect from the image change (image biomarkers).  Image biomarkers are more likely to detect 
subtle changes due to differences in RBE that may be difficult to detect clinically.  While image 
changes do not always lead to permanent adverse neurological defects58,75–77, they are still 
considered to be at least a grade 1 response according to the Common Terminology Criteria for 
Adverse Events (CTCAE) v4.078 grading scale and may be a harbinger of more severe 
reactions79,80.  It is also worth noting that sample size requirements for image biomarker-based 
analysis is likely to be smaller than the traditional approach of correlating dose-volume indices 
with toxicities81.  Being able to predict and potentially prevent post-treatment central nervous 
system (CNS) image change would ultimately improve treatment designs and, therefore, 
outcomes.  The methodologies developed may also be applicable to other patient datasets and 
disease sites.  
Previous studies have focused on applying pre-existing models of variable proton RBE for 
the analysis of patient cases82,83.  To date no significant correlations between increased RBE and 
observable treatment responses have been found.  I have specifically avoided the use of existing 
RBE models in the final analysis of image changes so as to not constrain the results of the 
analysis to a pre-determined model.  Such models have largely been developed from in vitro 
data, and there is no certainty that in vivo response would follow the same pattern.   
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      The probit form of the model was chosen primarily because many previous dose 
response studies in radiation oncology have used the Lyman NTCP computation model, which 
is a probit model48.  As the published Lyman model does not have an LET component, it was 
not appropriate for use here in its standard form.  I was, however, able to extract the TD50 
parameter since my model is based on the probit function.  This allows one to relate the results 
back to the more traditional models and analyses.  Published values for TD50 of 
necrosis/infarction in the brain (the most closely related normal tissue effect for which there is a 
large collection of reported data) for photons are in the range of 60-75 Gy48,50,84,85.  My analysis 
indicates that, for this set of patients, the TD50 for voxel image change spans a similar range for 
typical low proton LET values of 0-2 keV µm-1.  Such low LET values are common in the 
entrance region and portions of the target volume and have a similar biological effect as 
photons20.  Lower LET values correspond to higher TD50 values which translates to decreased 
biological effectiveness.  Finally, higher LET protons correspond to lower TD50 values, which 
in turn corresponds to greater biological effectiveness.  Here these LET values are in line with 
those near the end of the range of protons.  Assuming a TD50 of 65 Gy for brain necrosis for 
photons, the ratio of the photon values to that of protons eventually exceeds 1.1, which is the 
currently assumed value for proton RBE for clinical purposes.  It should be noted that to my 
knowledge there is no definitive TD50 for image changes reported for photon radiotherapy, yet 
these changes do represent early tissue damage. 
      Cross validation of the model by leaving out sets of data from individual patients 
indicated that the model could still perform well for each patient without their data being 
incorporated into the parameter fitting.  The high value of the cross-validated AUC is viewed as 
a good indication that that model could be applied to patients outside of this cohort and still 
achieve favorable results.  It should be noted, however, that the intended purpose of the model is 
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not to specifically identify voxels that will exhibit image change, but rather to provide a value 
for risk of change that can be used to optimize a plan in such a way as to reduce this risk. 
 
5.2. Limitations 
There are a number of limitations associated with this study that should be stated.  One 
prevalent limitation is that LETt is used for the treatment plan and outcomes analysis as opposed 
to LETd.  This is due to the fact that the MCNPX code used could not reasonably produce LETd 
data for the patient geometries involved in the study.  I would argue, though, that the impact of 
the use of LETt is negligible because the LET values observed for the treatment plans were 
generally low, and in this region of LET values, LETt and LETd are nearly equivalent
12.  
Nonetheless, this issue could be overcome in the future by using a more efficient Monte Carlo 
code that could produce LETd data. 
Another issue related to LET is that an average LET value was employed for the voxel-
based analysis.  With more advanced Monte Carlo simulations, it would be possible to record 
information about the spectrum of LET values encountered in each voxel.  In particular, this 
could help identify areas in which some proportion of the individual proton LET values are 
higher and thus produce more biological damage.  Analyzing this data could provide a better 
realization of the effect of proton LET as it relates to the observed outcomes. 
With the respect to the image data utilized in the study, a simplistic approach was taken.  
MR images were rigidly registered to treatment planning CT images.  This method could fail to 
capture more subtle changes in the location of the soft tissue and thus affect the spatial 
relationship between the dose and the image changes.  This could be overcome through the 
utilization of deformable image registration, which uses a greater number of anatomical land 
marks to non-uniformly deform the MR images to the CT images. 
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One of the potentially more difficult limitations to address is the assumption that the 
response of individual voxels is independent from other voxels.  The data represents a biological 
system in which the response of a subunit of tissue is affected by the response and changes in 
adjacent tissue.  It was accepted that, as a first approach, assuming voxel independence was 
reasonable due to the lack of a better model.  The exact initiating cause of the observed image 
changes is still poorly understood.  The causes of symptomatic brain tissue damage are currently 
thought to be attributable to changes in vasculature or direct damage to supporting glial cells, or 
likely some combination of both of these effects86–90.  Future research could eventually identify 
these mechanisms, which could potentially be incorporated to define better outcome models. 
 
5.3. Significance and Future Directions 
To date the vast majority of studies investigating the biological effects of protons have been 
focused on in vitro cellular response to different proton dose and LET11,19,20.  A large volume of 
data has been collected, but the published values for proton RBE continue to have large 
uncertainties due to many factors.  Examples of such confounding factors include differences in 
dose and, in particular, LET calculation methods, differences in cell survival experiment 
methodology, inadequate reporting of experimental design and Monte Carlo calculation details, 
which can preclude reproduction of studies, and differences in data fitting methods.  These 
factors can lead to differences between experimental data and models if the models were fit 
based on previous experiments.  This study has shown that high-throughput and consistently 
reproducible radiobiological experiments may provide a more clear picture of proton RBE, 
including a nonlinear relationship between RBE and LET, which would be difficult to observe 
in the collected data from multiple institutions.    This only further serves to highlight that 
proton RBE is an inherently uncertain quantity, and it will likely remain this way for some time. 
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Part of the analysis in this study was thus conducted with the goal of shifting the dialog 
away from RBE and instead toward the understanding of outcomes simply based on the physical 
properties of protons -- dose and LET.  An advantage of this approach is that it provides the 
opportunity to become directly knowledgeable of the proton biological effects that are of 
greatest interest, i.e. those tied to observable clinical outcomes.  As previously stated, this 
approach is limited due to lack of sufficient outcomes data in many cases.  It can also be 
difficult to draw substantial conclusions from patient cohorts for which the size of the observed 
effect is small.  This was likely the case for a similar study by Giantsoudi et al.82 which 
analyzed treatment outcomes for a cohort of patients treated for medulloblastoma.  In a cohort 
of 111 patients, only 4 were observed to have symptomatic normal tissue complications.  The 
study may have further been limited by analyzing patient data based on volumetric indices. 
Previous models for normal tissue complications have been based on dose-volumetric 
data48,49,51.  While this methodology has been well studied, it may not be the most effective 
approach for analyzing proton therapy outcomes.  Dose-volume indices represent averages over 
volumes and can thus hide positional information.  While photon therapy has a reasonably 
constant LET value, proton therapy has an inherently spatially variant LET value.  Thus, volume 
averaging of proton plan indices such as LET or values linked to LET, such as variable RWD, 
may wash out valuable information about focal areas of interest.  DVH metrics do provide some 
value in observing these effects, but given the amount of computational power now available, it 
only makes sense to consider analyzing data on a voxel-by-voxel basis, especially considering 
that imaging technology can now provide a wealth of functional information at the voxel level.  
This study has provided strong evidence that such an approach can potentially enhance the value 
of the limited number of proton outcome studies currently available because it utilizes a greater 
amount of data from each patient. 
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In the current study, all patients were treated with passive scattering proton therapy. This is a 
traditional technique that allows little flexibility, similar to photon based 3D conformal radiation 
therapy.  As with photon treatments, which have evolved to IMRT, pencil beam scanning 
technology is now allowing additional flexibility in proton planning and delivery with IMPT.  
This technology provides greater capability for advanced optimization techniques based on the 
simultaneous optimization of multiple treatment beams based on the placement of individual 
beamlets.  This is important to highlight because the results of this study would be difficult to 
implement in PSPT treatment planning due to the limitations on plan optimization. 
The development of proton biological effectiveness models is typically done with the 
intention of applying the model to evaluate the potential outcome of a given plan and to 
optimize plans to achieve better outcomes.  The case is no different here.  Using IMPT, the 
probability of image change provided by my model could be used in treatment plan evaluation 
and optimization, and in fact, this is included in my own plans for future research.  I foresee 
being able to implement the model for probability of image change in a voxel into proton plan 
optimization as a constraint in the objective function.  A goal for the optimization could then be 
to keep the probability of image change value as low as reasonably achievable or at least below 
a pre-specified level.  A planning study with this technique could be performed for this patient 
cohort to determine if, through changes in optimization, the probability of image change could 
be reduced while maintaining the standard-of-care plan quality.  Such a study, if successful, 
would provide strong evidence to support a clinical trial in which traditional planning and 
optimization were compared to the new method with the goal of reducing normal tissue effects. 
In addition, my method is easily generalizable to any other anatomical site for which there is 
a response that can be identified by imaging.  As it stands, my model was used only for MR 
image changes in the brain, but it could be expanded to other imaging modalities.  Advanced 
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imaging modalities which provide quantitative functional information could potentially greatly 
improve my model.  Being able to tie information on functional anatomical changes back to 
proton physical properties could pave the way for a new generation of proton biological effects 
models for a number of different outcomes of interest. 
Moreover to improve upon the current results, considerable further research can be 
performed to improve the accuracy of underlying data used in the analyses and improve the 
accuracy and robustness of the model and its predictive power.  One of the immediate shifts to 
be made will be to compute the patient treatment plans with a track-repeating algorithm capable 
of calculating LETd, as well as variable RWD without the need for such significant post 
processing91–95.  This rapid calculation technique would also allow for more laborious 
calculations for specific cases of interest.  One specific example of this type of calculation 
would be the collection of proton energy or LET spectra on a voxel basis.  This data could be 
used to gain a better understanding of how higher LET components of average LET may play a 
role in observed biological effects. 
To conclude, I have been able to show that proton radiation induced imaging changes in the 
brain and brainstem are related not only to proton dose but also LET and thus the variable 
biological effectiveness of protons.  The developed model has potential for improving patient 
treatment plans through its incorporation into plan evaluation and optimization.  The voxel-
based analysis performed here could be extended to other sites and imaging modalities, which 
holds promise to further expand the knowledge of in vivo variable proton biological 
effectiveness. 
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